Neutralizing Anti-SARS-CoV-2 Antibodies for Broad Strain Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need for effective prophylactics and therapeutics to prevent and treat SARS-COV-2 infection, particularly due to its airborne transmission and the lack of available methods for immunization, diagnosis, and treatment.
Innovation Solution
Development of neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments that specifically bind to the SARS-COV-2 spike protein, particularly the receptor-binding domain, capable of neutralizing multiple virus strains, with specific amino acid sequences for heavy and light chain variable regions, and potentially multivalent or bispecific configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional antiviral approaches are used, then treatment options are limited, but the virus spreads rapidly through airborne transmission
Solution Approach 1:
The patent develops and provides neutralizing antibodies in advance before SARS-CoV-2 infection occurs, enabling prophylactic protection. The antibodies are prepared and characterized beforehand to neutralize multiple virus strains, allowing individuals to receive protective treatment prior to exposure rather than waiting for infection to occur
Solution Approach 2:
The neutralizing antibodies described in the patent are designed to recognize and bind to conserved epitopes on the SARS-CoV-2 spike protein that are common across multiple virus strains. This multi-strain neutralization capability provides universal protection against different SARS-CoV-2 variants, making a single antibody formulation effective against a broad range of viral configurations
2Adaptability or versatility
If vaccines are developed rapidly, then immunization can be provided, but the complexity of viral variants makes effective target identification difficult
Solution Approach 1:
The patent focuses on targeting specific local regions (epitopes) on the SARS-CoV-2 spike protein that are conserved across multiple virus strains. By identifying and neutralizing these specific local structures rather than attempting to address the entire complex viral surface, the antibodies achieve broad strain coverage while maintaining a focused, manageable target approach
Solution Approach 2:
The patent employs phage display technology and iterative selection processes to identify antibody variants with optimized binding parameters to conserved spike protein epitopes. Through systematic variation and selection of antibody parameters (affinity, specificity, neutralization potency), the invention identifies optimal antibody configurations that effectively neutralize multiple virus strains despite the complexity of the viral target
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies provide prophylactic and therapeutic protection against SARS-COV-2 by neutralizing the virus, offering a novel therapeutic strategy for preventing and treating infections, including those caused by multiple strains.
Implementation Method 1
anti-SARS-COV-2 antibodies or antigen-binding fragments that specifically bind to the SARS-COV-2 spike protein, particularly the receptor-binding domain
Implementation Method 2
capable of neutralizing multiple virus strains
Data Source
AI summary
This disclosure provides novel neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-COV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-COV-2 infections.